201 related articles for article (PubMed ID: 30600364)
1. Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).
Lopez CL; Joos B; Bartsch DK; Manoharan J; Albers M; Slater EP; Bollmann C; Roth S; Bayer A; Fendrich V
World J Surg; 2019 Mar; 43(3):831-838. PubMed ID: 30600364
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse Model.
Manoharan J; Fendrich V; Di Fazio P; Bollmann C; Roth S; Joos B; Mintziras I; Albers MB; Ramaswamy A; Bertolino P; Zhang CX; Slater EP; Bartsch DK; Lopez-Lopez CL
Neuroendocrinology; 2018; 107(3):257-266. PubMed ID: 30025403
[TBL] [Abstract][Full Text] [Related]
3. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
4. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
5. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.
Bartsch DK; Slater EP; Albers M; Knoop R; Chaloupka B; Lopez CL; Fendrich V; Kann PH; Waldmann J
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2387-91. PubMed ID: 25210877
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.
Walls GV; Stevenson M; Soukup BS; Lines KE; Grossman AB; Schmid HA; Thakker RV
Endocrinology; 2016 May; 157(5):1789-98. PubMed ID: 26990064
[TBL] [Abstract][Full Text] [Related]
7. Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.
Walls GV; Reed AA; Jeyabalan J; Javid M; Hill NR; Harding B; Thakker RV
Endocrinology; 2012 Nov; 153(11):5167-79. PubMed ID: 23024266
[TBL] [Abstract][Full Text] [Related]
8. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.
Quinn TJ; Yuan Z; Adem A; Geha R; Vrikshajanani C; Koba W; Fine E; Hughes DT; Schmid HA; Libutti SK
Surgery; 2012 Dec; 152(6):1068-77. PubMed ID: 23102680
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Imaging Overestimates the Tumor Size in Pancreatic Neuroendocrine Neoplasms Associated with Multiple Endocrine Neoplasia Type 1.
Polenta V; Slater EP; Kann PH; Albers MB; Manoharan J; Ramaswamy A; Mahnken AH; Bartsch DK
World J Surg; 2018 May; 42(5):1440-1447. PubMed ID: 29075857
[TBL] [Abstract][Full Text] [Related]
10. Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.
Marciello F; Di Somma C; Del Prete M; Marotta V; Ramundo V; Carratù A; de Luca di Roseto C; Camera L; Colao A; Faggiano A
Endocrine; 2014 Aug; 46(3):678-81. PubMed ID: 24385268
[TBL] [Abstract][Full Text] [Related]
11. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):6-7. PubMed ID: 27168103
[No Abstract] [Full Text] [Related]
12. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
[TBL] [Abstract][Full Text] [Related]
13. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
16. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
[TBL] [Abstract][Full Text] [Related]
17. Accelerated proliferation and differential global gene expression in pancreatic islets of five-week-old heterozygous Men1 mice: Men1 is a haploinsufficient suppressor.
Lejonklou MH; Barbu A; Stålberg P; Skogseid B
Endocrinology; 2012 Jun; 153(6):2588-98. PubMed ID: 22492302
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review.
La Salvia A; Sesti F; Grinzato C; Mazzilli R; Tarsitano MG; Giannetta E; Faggiano A
Pharmaceuticals (Basel); 2021 Oct; 14(10):. PubMed ID: 34681263
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
